- Verastem Oncology's (VSTM, Financial) Phase 2 RAMP 201 trial results published in the Journal of Clinical Oncology.
- Combination of avutometinib and defactinib shows significant clinical benefits in low-grade serous ovarian cancer.
- FDA approves combination for KRAS-mutated recurrent low-grade serous ovarian cancer.
Verastem Oncology (VSTM) announced that the primary analysis from the Phase 2 RAMP 201 clinical trial has been published in the Journal of Clinical Oncology. The study evaluated the efficacy and safety of a combination therapy of avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC).
The trial demonstrated a robust overall response rate (ORR) of 31% in all patients, with a notably higher ORR of 44% in those with a KRAS mutation. The study also reported a median progression-free survival (PFS) of 12.9 months overall, extending to 22.0 months in the KRAS-mutant group.
Based on these findings, the combination therapy has received FDA approval for use in treating KRAS-mutated recurrent LGSOC, a decision that aligns with its designation as an NCCN Category 2A recommendation. The treatment is well-received with an 82% reduction in target lesions in patients, regardless of KRAS mutation status.
Verastem continues to advance its research with the ongoing global Phase 3 RAMP 301 trial, exploring the combination's efficacy in patients both with and without KRAS mutations. The company is also preparing to submit the RAMP 201 results to the National Comprehensive Cancer Network® (NCCN®) for potential guideline inclusion.
For more detailed information about Verastem and its ongoing studies, please visit their website and follow them on LinkedIn.
